Regenerative medicine cell therapies: numbers of units manufactured and patients treated between 1988 and 2010

Bibliography

• 1  Kemp P: History of regenerative medicine: looking backwards to move forwards. Regen. Med.1(5),653–669 (2006).
  Google Scholar
• 2  Lysaght MJ, Crager J: Origins. Tissue Eng. Part A15(7),1449–1450 (2009).
  MedlineGoogle Scholar
• 3  Mason C, Dunnill P: A brief definition of regenerative medicine. Regen. Med.3(1),1–5 (2008).
  Google Scholar
• 4  Mason C, Manzotti E: Regen: the industry responsible for cell-based therapies. Regen. Med.4(6),783–785 (2009).
  Google Scholar
• 5  Martin PA, Coveney C, Kraft A, Brown N, Bath P: Commercial development of stem cell technology: lessons from the past, strategies for the future. Regen. Med.1(6),801–807 (2006).
  Google Scholar
• 6  Lysaght MJ, Jaklenec A, Deweerd E: Great expectations: private sector activity in tissue engineering, regenerative medicine, and stem cell therapeutics. Tissue Eng. Part A14(2),305–315 (2008).
  MedlineGoogle Scholar
• 7  Mason C: ISSCR 2009 Industry Panel Session: promoting translation and commercialization. Cell Stem Cell5(4),379–384 (2009).
  Medline CASGoogle Scholar
• 8  Mason C, Dunnill P: The need for a regen industry voice. Regen. Med.3(5),621–631 (2008).
  Google Scholar
• 9  Leonard EF, Morgan JR, Nerem RM: In remembrance: Michael J Lysaght, 1942–2009. Tissue Eng. Part A16(3),767–768 (2010).
  MedlineGoogle Scholar
• 10  Lysaght MJ, Hazlehurst AL: Tissue engineering: the end of the beginning. Tissue Eng.10(1–2),309–320 (2004).
  MedlineGoogle Scholar
• 11  Plagnol AC, Rowley E, Martin P, Livesey F: Industry perceptions of barriers to commercialization of regenerative medicine products in the UK. Regen. Med.4(4),549–559 (2009).
  Google Scholar
• 12  Hunziker E, Spector M, Libera J et al.: Translation from research to applications. Tissue Eng.12(12),3341–3364 (2006).
  Medline CASGoogle Scholar
• 13  Ehrenreich M, Ruszczak Z: Update on tissue-engineered biological dressings. Tissue Eng.12(9),2407–2424 (2006).
  Medline CASGoogle Scholar
• 14  Vemuganti GK, Sangwan VS: Affordability at the cutting edge: stem cell therapy for ocular surface reconstruction. Regen. Med.5(3),337–340 (2010).
  Google Scholar
• 15  Bertram T: Company profile: Tengion. Regen. Med.4(3),359–364 (2009).
  Google Scholar
• 16  Ilic D: Latest developments in stem cell research and regenerative medicine. Regen. Med.4(1),11–25 (2009).
  Google Scholar
• 17  Ilic D: Industry Report. Regen. Med.5(3),323–330 (2010).
  Google Scholar
• 18  Ginty P, Singh PB, Smith D, Hourd P, Williams DJ: Achieving reimbursement for regenerative medicine products in the USA. Regen. Med.5(3),463–469 (2010).
  CASGoogle Scholar
• 19  Kemp P: Cell therapy – back on the up-curve. Interview with Paul Kemp by Elisa Manzotti. Regen. Med.1(1),9–14 (2006).
  Google Scholar
• 101  House of Commons, Science and Technology Committee. Bioengineering Seventh Report of Session 2009–10. 17 March 2010 www.parliament.uk/parliamentary_committees/science_technology/s_t_bioengineering_inquiry.cfm
  Google Scholar
• 102  Martin P, Hawksley R, Turner A: The commercial development of cell therapy – Lessons for the future? Institute for Science and Society, University of Nottingham. April 2009 – Part 1 (Summary of findings) and Part 2 (Data tables and charts) www.nottingham.ac.uk/iss/research/Current-Research-Projects/Staff_projects/regenmed/reports_publications.htm
  Google Scholar
• 103  US FDA CFR – Code of Federal Regulations Title 21 www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=1271
  Google Scholar